Evidence Hub

Case Report: First In-Human Report of Cure of Refractory Mycoplasma genitalium Infection With Omadacycline

Patel NM

Open forum infectious diseases, 2026

Abstract

Mycoplasma genitalium (MG) is increasingly recognized as a sexually transmitted cause of nongonococcal urogenital infections. MG demonstrates high rates of antimicrobial resistance, and there are few available treatment options for infections caused by multidrug-resistant organisms. There is a paucity of guidance on the management of MG infections in which initial therapy fails, and additional globally accessible treatments are needed to address this rising clinical challenge. This report describes the first in-human case of refractory MG infection that was cured after treatment with omadacycline.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free